{"id":"NCT00986570","sponsor":"Biolab Sanus Farmaceutica","briefTitle":"Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face","officialTitle":"Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2010-06","completion":"2010-11","firstPosted":"2009-09-30","resultsPosted":"2010-12-06","lastUpdate":"2015-12-11"},"enrollment":121,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Skin Aging"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxin A","otherNames":["Xeomin®"]}],"arms":[{"label":"Xeomin®","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determinate whether Xeomin® (Botulinum toxin Type A) is safe, effective and tolerable in woman aged 30 to 50 years old for treatment of mild, moderate or severe expression lines (wrinkles) in the upper third of the face. The main outcome was the change in appearance of the wrinkles two weeks (visit 3) after product application as compared with baseline assessment.","primaryOutcome":{"measure":"Treatment Success","timeFrame":"Baseline (pre-treatment) and Visit 3 (Day 15)","effectByArm":[{"arm":"Xeomin®","deltaMin":89.08,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":1,"countries":["Brazil"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":["Injection-site bleeding","Headache","Injection-site pain","Deformity","Injection-site pruritus"]}}